| 摘要 |
The present invention relates to the use of an angiotensin-converting enzyme inhibitor, such as ramipril, to reduce or prevent Type 2 diabetes in high risk patients. The present invention also relates the use of an angiotensin-converting enzyme inhibitor, such as ramipril, to reduce the decline of beta-cell function, increase islet blood flow, lower aldosterone secretion, lower renal potassium wasting, increase pancreatic beta-cell perfusion, reduce insulin resistance in skeletal muscles, and increase insulin-mediated glucose disposal and uptake by skeletal muscles. |
